Pinealon
Pinealon • Also called Pinealon Acetate
Pinealon is a biohacking-market peptide associated with cognitive and longevity interest, but we do not currently have a clear FDA category, warning-letter placement, or approved-drug pathway to point to for it.
Current status
Restricted
Cognitive and longevity interest, with current federal compounding constraints still in play.
FDA category
No clear FDA signal
Can pharmacies compound this?
No
Reclassification expected?
Unclear
This page is tracked because Pinealon is a real search term in the peptide market, not because FDA has given it a defined path. Until a clearer federal signal appears, the safer assumption is that routine pharmacy compounding remains difficult to defend.
Primary Use
Cognitive and longevity interest
Also searched as
Pinealon Acetate
Regulatory Timeline
Mar 23, 2026
Current status signal recorded: No clear FDA category, warning-letter placement, or approved-drug pathway identified yet; current restriction is an inference from the lack of a documented lawful compounding basis..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Pinealon status changes
State-specific notes
California
Without a clearer federal footing, specialty peptide sourcing is likely to stay highly conservative.
Florida
Online discussion may outpace what compliant pharmacies are willing to dispense.